Skip to main content
[Preprint]. 2023 Nov 20:2023.11.20.23298785. [Version 1] doi: 10.1101/2023.11.20.23298785

Table 1:

Clinical Characteristics of study participants Unless specified, all data are presented as n (%N);

Arm A Full-dose Ad26.COV2.S Arm B Half-dose Ad26.COV2.S Arm C Full-dose BNT162b2 Arm D Half-dose BNT162b2 Total

Vaccinated (N) 74 69 73 73 289

Age * 42 (35–48) 40 (35–45) 43 (35–50) 42 (35–49) 42 (35–49)
 18–29 years 5 (6.8%) 5 (7.2%) 7 (9.6%) 6 (8.2%) 23 (8%)
 30–44 years 41 (55.4%) 46 (66.7%) 34 (46.6%) 34 (46.6%) 155 (53.6%)
 45–54 years 20 (27%) 10 (14.5%) 23 (31.5%) 22 (30.1%) 75 (26%)
 ≥ 55 years 8 (10.8%) 8 (11.6%) 9 (12.3%) 11 (15.1%) 36 (12.5%)

Sex
 Male 10 (13.5%) 8 (11.6%) 18 (24.7%) 15 (20.5%) 51 (17.6%)
 Female 64 (86.5%) 61 (88.4%) 55 (75.3%) 58 (79.5%) 238 (82.4%)

Ethnicity
 Black African 69 (93.2%) 67 (97.1%) 69 (94.5%) 70 (95.9%) 275 (95.2%)
 Other 5 (6.8%) 2 (2.9%) 4 (5.5%) 3 (4.1%) 14 (4.8%)

Days between prime and Booster* 265 (245–292) 271 (259–302) 273 (258–291) 272 (253–300) 271 (255–296)

BMI
 Underweight 0 (0%) 2 (2.9%) 0 (0%) 1 (1.4%) 3 (1%)
 Normal 12 (16.2%) 8 (11.6%) 14 (19.2%) 6 (8.2%) 40 (13.8%)
 Overweight 20 (27%) 41 (59.4%) 39 (53.4%) 47 (64.4%) 71 (24.6%)
 Obese 41 (55.4%) 39 (56.5%) 47 (64.4%) 47 (64.4%) 174 (60.2%)
 Not available 1 (1.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)

HIV infection
 HIV Positive 27 (36.5%) 28 (40.6%) 31 (42.5%) 30 (41.1%) 116 (40.1%)
 Viremic$ 1 (3.7%) 5 (17.9%) 4 (12.9%) 6 (20%) 16 (13.8%)
  CD4 count (cells/mm3)* 223 (na) 452 (103–471) 1136 341 (132–538) 452 (132–538)
  Viral load (copies/mL)* 818 5838 29911 19960 15376
na (3054–18252) (14863–47207) (5324–37713) (3054–27420)
 Aviremic$ 26 (96.3%) 23 (82.1%) 27 (87.1%) 24 (80%) 100 (86.2%)
  CD4 count (cells/mm3)* 698 (580–923) 677 (530–855) 812 (623–931 666 (538–737) 708 (558–922)

Prior SARS-CoV-2 infection & 51/58 (87.8%) 52/57 (91.2%) 55/59 (93.2%) 55/59 (93.2%) 213/223 (91.4%)

Co-morbidities
 Hypertension 19 (25.7%) 8 (11.6%) 17 (23.3%) 17 (23.3%) 61 (21.1%)
 Anaemia 7 (9.5%) 8 (11.6%) 6 (8.2%) 9 (12.3%) 30 (10.4%)
 Asthma 6 (8.1%) 3 (4.3%) 2 (2.7%) 1 (1.4%) 12 (4.2%)
 Diabetes mellitus 3 (4.1%) 1 (1.4%) 4 (5.5%) 4 (5.5%) 12 (4.2%)
 Arthritis 1 (1.4%) 0 (0%) 3 (4.1%) 3 (4.1%) 7 (2.4%)
 Tuberculosis 0 (0%) 4 (5.8%) 2 (2.7%) 0 (0%) 6 (2.1%)

Retention
 W2 visits completed 74 (100%) 66 (95.7%) 72 (98.6%) 69 (94.5%) 281 (97.2%)
 W12 visits completed 74 (100%) 67 (97.1%) 67 (91.8%) 70 (95.9%) 278 (96.2%)
 W24 visits completed 69 (93.2%) 63 (91.3%) 69 (94.5%) 68 (93.2%) 269 (93.1%)
*

median and interquartile range (IQR);

$

% is of all HIV-infected participants; Viremic individuals were defined as having a HIV-1 viral load (VL) >200 HIV mRNA copies/mm3; 3 participants in the viremic arm C had a missing CD4 count;

&

Prior SARS-CoV-2 infection was defined by the presence of Nucleocapsid-specific IgG; na: non-applicable.